Paclitaxel for treating KS
- PMID: 11365372
Paclitaxel for treating KS
Abstract
AIDS: Paclitaxel (Taxol) received Food and Drug Administration (FDA) approval for use as a second-line therapy, in combination with G-CSF growth factor, for treating Kaposi's sarcoma (KS). Paclitaxel study results are highlighted showing that those patients who responded to Paclitaxel did so in about 2 months with a duration of 9 months, and some sustained responses for upwards of 2 years. Chemotherapies encapsulated in fat that appear to be more effective and less toxic than traditional combination chemotherapy regimens are also highlighted. Two such KS therapies, liposomal daunorubicin (DaunoXome) and liposomal doxorubicin (Doxil), have been approved for use. More information can be obtained by contacting the Project Inform Hotline.
Similar articles
-
Kaposi's sarcoma: DaunoXome approved.AIDS Treat News. 1996 May 3;(no 246):3-4. AIDS Treat News. 1996. PMID: 11363485
-
KS treatment inches forward.Posit Aware. 1996 Sep-Oct;7(5):9. Posit Aware. 1996. PMID: 11363790
-
Liposomal chemotherapies.GMHC Treat Issues. 1995 Jul-Aug;9(7/8):13. GMHC Treat Issues. 1995. PMID: 11362653
-
Paclitaxel for AIDS-associated Kaposi's sarcoma.Expert Rev Anticancer Ther. 2005 Apr;5(2):215-9. doi: 10.1586/14737140.5.2.215. Expert Rev Anticancer Ther. 2005. PMID: 15877519 Review.
-
Use of liposomal anthracyclines in Kaposi's sarcoma.Semin Oncol. 2004 Dec;31(6 Suppl 13):36-52. doi: 10.1053/j.seminoncol.2004.08.003. Semin Oncol. 2004. PMID: 15717737 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical